RENO, NV, June 1, 2010 -- Liberty Silver Corp. (OTCBB: LBSV) ("Liberty" or the "Company") is pleased to announce that it has retained Mine Development Associates Inc. (MDA) of Reno, Nevada, a full service mining engineering firm, to construct an updated and NI 43-101 compliant inferred resource estimate and deposit model of the known Trinity silver deposit.
Liberty Silver Corp. closed at $1.07 Friday, trading 465,306 shares.
Liberty Updates Open Pit Optimization and Resource Estimates
About Liberty Silver Corp.
Liberty Silver Corp., a publicly held American company traded on the OTCBB as LBSV, is focused on exploring and developing mineral properties located in North America. The Company is led by a highly skilled, experienced management team and board of directors with decades of success managing exploration, development and mining projects. The Company is committed to creating value for its shareholders by advancing its current projects to production, developing new resources on its current properties, and by acquiring new properties that have potential to increase their resource base.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
CORAL SPRINGS, FL, June 1, 2010 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has partnered with leading healthcare products distributor, Henry Schein, for distribution of its Nyloxin-branded pain relievers in the United States.
Nutra Pharma Corp. closed at $0.29 Friday, trading 812,551 shares.
Nutra Pharma Partners With Henry Schein for Distribution of Nyloxin-Branded Pain Relievers
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.
In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.
The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).
Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.
For additional penny stock news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free penny stock company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded penny stock companiesand investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer
-------------------------------------------
Keywords: penny stock, penny stock news, penny stock alerts, penny stock updates, penny stock news updates, penny stock profile
Posts
No comments:
Post a Comment